Chronic myeloid leukemia, or CML, is one of those diseases where modern medicine has already pulled off something pretty wild: for many people, a once-scary blood cancer became a long-term manageable condition thanks to tyrosine kinase inhibitors, or TKIs. But picture this - if the first few TKIs stop working well enough, or the side effects turn daily life into a part-time job, the whole treatment map starts looking less like a highway and more like a badly drawn subway diagram with coffee spilled on it.
That is where the new ASC4OPT study steps in.[1] It looked at asciminib, a CML drug with a different trick. Most TKIs try to block BCR::ABL1, the engine driving CML, by jamming the ATP site - basically the usual front door. Asciminib goes for the myristoyl pocket, a different site on the same protein. Same villain, different choke point. Cancer, inconveniently creative as always, does not love that.
The “third try” problem
CML is caused by the Philadelphia chromosome, which creates the BCR::ABL1 fusion protein, a molecular gas pedal stuck to the floor.[2][3] TKIs have changed lives here, no question. But after two or more prior TKIs, things get messier. Some patients develop resistance. Others simply cannot tolerate the drugs. And in CML, “can’t tolerate” does not mean “mildly annoying.” It can mean fatigue, gastrointestinal misery, cardiovascular risk, muscle pain, or a thousand other ways for a pill to become your least favorite roommate.
ASC4OPT focused on exactly that crowd: adults with chronic-phase CML who had already been through at least two TKIs and were still not where doctors wanted them to be.[1]
A smarter lockpick, not a bigger hammer
Imagine BCR::ABL1 as a broken machine with two ways to shut it down. Old-school TKIs throw a wrench into the spinning gears. Asciminib slips around the side and hits a hidden safety switch. That matters because tumors that learn how to dodge one kind of blockade may still get caught by the other.[3]
This is why hematologists have been paying close attention to asciminib for a few years now. In the earlier ASCEMBL trial, asciminib already beat bosutinib in patients who had received at least two prior TKIs, with better molecular response and a friendlier side-effect profile.[4] Longer-term phase 1 data also suggested those responses could last, which is the kind of sentence oncologists enjoy almost as much as free conference coffee.[5]
What ASC4OPT actually found
The headline result is simple: asciminib kept helping a meaningful chunk of heavily pretreated patients reach major molecular response, or MMR.[1]
MMR is not a magic word, but it is an important one. It means the leukemia signal in the blood has dropped to a very low level. Think of it as the disease’s microphone getting turned way, way down.
In ASC4OPT, among patients not already in MMR at baseline, about 39.4% reached MMR by week 48, and 43.6% did so by week 96.[1] The twice-daily 40 mg schedule numerically edged out the once-daily 80 mg schedule, though both showed activity. For patients who were already in MMR when they entered because they were intolerant rather than resistant, most stayed there through follow-up.[1]
That last bit matters more than it might seem. In CML, success is not just about getting a response. It is about holding onto it without making the patient miserable. A treatment that works but wrecks quality of life is a bit like owning a sports car with a horn that screams for six hours every time you turn left.
Safety in ASC4OPT looked consistent with what researchers had already seen with asciminib.[1] That does not mean side effects vanish in a puff of optimism. It means the drug behaved in a way clinicians broadly expected, which is exactly what you want when treating people who have already been through a lot.
Why this is a big deal outside the lab
The real intrigue here is not just the percentage on a graph. It is what those percentages represent.
For someone with CML who has already cycled through multiple TKIs, every next step can feel narrower, riskier, and more exhausting. ASC4OPT suggests asciminib is not merely a backup option shoved into the corner of the medicine cabinet. It is looking more and more like a real standard-of-care anchor for patients whose disease has not cooperated with earlier therapies.[1][4][5]
And the broader story is moving fast. On October 29, 2024, the FDA granted accelerated approval to asciminib for newly diagnosed Philadelphia chromosome-positive CML in chronic phase, which tells you this drug is already migrating from “rescue mission” territory toward earlier use in the treatment timeline (FDA announcement). That is not proof it solves every problem. But it does suggest the field sees this mechanism as more than a one-off curiosity.
In other words, asciminib may be less like a spare tire and more like a better route the GPS should have suggested earlier.
The catch, because biology always brings one
This was a non-comparative phase 3b study, so it does not directly settle every dosing question or every head-to-head debate.[1] Resistance biology is still complicated. Not every patient responds. Dose escalation helped some patients, but not a dramatic number.[1] And CML treatment is still a long game involving monitoring, adherence, mutation patterns, and side-effect tradeoffs that are about as glamorous as tax season.
Still, if you zoom out, ASC4OPT adds another solid piece to the picture: in a disease where many patients do well early but some get stranded later, asciminib keeps looking like a smarter and more durable bridge.
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.
References
-
Hochhaus A, le Coutre P, Milojkovic D, et al. ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors. Leukemia. 2026. DOI: https://doi.org/10.1038/s41375-026-02965-8
-
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703-1719. DOI: https://doi.org/10.1038/s41375-022-01613-1
-
Rea D, Hughes TP. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Crit Rev Oncol Hematol. 2022;169:103580. DOI: https://doi.org/10.1016/j.critrevonc.2022.103580
-
Hochhaus A, Rea D, Boquimpani C, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617-626. DOI: https://doi.org/10.1038/s41375-023-01829-9
-
Hochhaus A, Kim DW, Cortes JE, et al. Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results. Leukemia. 2025;39:1114-1123. DOI: https://doi.org/10.1038/s41375-025-02578-7 | PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC12055594/
-
Hijiya N, Mauro MJ. Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes. Cancer Manag Res. 2023;15:873-891. DOI: https://doi.org/10.2147/CMAR.S353374 | PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC10460573/